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Abstract 
Hepatitis E virus (HEV) is one of the prime causes of acute viral hepatitis, whereas chronic 
hepatitis E is increasingly recognized as an important problem in the transplant setting. 
Nevertheless, the fundamental understanding of the biology of HEV replication is limited and 
there are few therapeutic options. The development of such therapies is partially hindered by 
the lack of a robust and convenient animal model. We propose the infection of athymic nude 
rats with the rat HEV strain LA-B350 as such a model. A cDNA clone pLA-B350 was 
constructed and the infectivity of its capped RNA transcripts was confirmed in vitro and in 
vivo. Furthermore, a subgenomic replicon pLA-B350/luc was constructed and validated for in 
vitro antiviral studies. Interestingly, rat HEV proved to be less sensitive to the antiviral 
activity of alpha interferon, ribavirin and mycophenolic acid, than genotype 3 HEV. As a 
proof-of-concept, part of the C-terminal polymerase sequence of pLA-B350/luc was swapped 
with its genotype 3 HEV counterpart: the resulting chimeric replicon replicated with 
comparable efficiency as the wild-type construct, confirming that LA-B350 is amenable to 
humanization. Finally, ribavirin effectively inhibited LA-B350 replication in athymic nude 
rats, confirming the suitability of the rat model for antiviral studies.  
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
Introduction 
Hepatitis E virus (HEV) is a positive-sense single-stranded RNA virus classified in the 
Hepeviridae family. The virus is transmitted feco-orally and although most infections remain 
asymptomatic, HEV is one of the most common causes of acute viral hepatitis and is known 
to cause large water-borne epidemics in developing countries (Debing and Neyts, 2014; 
Wedemeyer et al., 2013). Such outbreaks are mainly due to infections with genotype 1 and 
are typically associated with high mortality rates in pregnant women (Khuroo et al., 1981; 
Tsega et al., 1993). Genotypes 3 and 4 are the main causes of hepatitis E in industrialized 
countries where infections occur mostly through consumption of undercooked pig meat 
(Dalton et al., 2014). Genotype 3 infections may evolve to chronicity in 
immunocompromised patients (e.g. transplant recipients, HIV-infected individuals,…) and 
often require either dose reductions of immunosuppressant drugs and/or treatment with 
ribavirin or pegylated alpha interferon (Kamar et al., 2011). Ribavirin is the drug of choice in 
most patients (Kamar et al., 2014), but has several side effects and treatment failure occurs 
occasionally (Debing et al., 2014d; Pischke et al., 2013). A robust and convenient animal 
infection model for hepatitis E will allow to further explore the modalities for antiviral 
therapy and to develop alternative treatment options for (chronic) hepatitis E. Currently 
available infection models such as those in chimpanzees and pigs are not convenient, whereas 
attempts to infect rodents with human HEV strains generated mixed outcomes and did not 
result in a robust animal model (Huang et al., 2009; Li et al., 2008; Li et al., 2013a; Li et al., 
2013b; Purcell et al., 2011). 
 
Rat HEV is another member of the Hepeviridae that has been isolated from wild rats and 
probably has a worldwide prevalence (Johne et al., 2010b; Mulyanto et al., 2014; Purcell et 
al., 2011). Rats seem to acquire the virus at an early age and infection generally proceeds 
without overt symptoms (Purcell et al., 2011). Rat HEV is classified in the Orthohepevirus C 
species according to recently proposed HEV taxonomy recommendations (Smith et al., 
2014), whereas human genotypes 1-4 are grouped under the Orthohepevirus A species. 
Furthermore, rat HEV strains are classified into 3 different genetic groups (Mulyanto et al., 
2014). Sequence identity between human and rat HEV is about 60% with several highly 
conserved motifs in key viral genes. 
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Since rat HEV can infect several types of laboratory rats (Li et al., 2013a; Purcell et al., 
2011), we aimed to employ this virus in a bona fide model for infections with Hepeviridae. 
The rat HEV strain LA-B350 was originally isolated from rats in Los Angeles, CA and was 
subsequently passaged in Sprague-Dawley rats and in an athymic nude hooded rat (B350) 
(Purcell et al., 2011). We recently determined the full-length genomic sequence of this strain 
and confirmed its classification into genetic group 1 (Debing et al., 2014a). Here we describe 
the establishment of the pLA-B350 cDNA clone and the corresponding subgenomic replicon 
pLA-B350/luc and the suitability of these constructs for antiviral studies.  
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Results 
Athymic nude rats, but not mice, are susceptible to rat HEV LA-B350 infection 
To develop a convenient and robust animal model for HEV using rat HEV strain LA-B350, 4 
athymic nude rats were injected intravenously with diluted liver suspension from rat B350 
(Purcell et al., 2011); in all 4 rats solid viral replication was observed (figure 1A-B). Rat 
HEV RNA was detected in the feces as early as 4 days post infection and increased to over 
109 copies g-1 feces by day 30; afterwards, fecal titers remained constant until day 60 post 
infection. Viral RNA was detected in rat serum as well, although at considerably lower titers 
compared to the feces, reaching a maximum of 4 x 106 copies ml-1 serum (figure 1A). After 
60 days, viral RNA levels in the liver reached over 1010 copies g-1 liver (figure 1B). These 
titers are higher than those reported by others (Li et al., 2013a; Purcell et al., 2011), which 
may be the result of the extended time frame and/or adaptation to the host. No marked 
alterations were observed in levels of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) or gamma-glutamyltransferase (γGT) in serum (figure S1). 
Concordantly, histopathological evaluation of haematoxylin-eosin-stained liver sections 
revealed only very limited evidence for portal tract infiltration by lymphocytes and 
polymorphonuclear leucocytes in infected animals, with no significant differences compared 
to uninfected control rats (figure 1D). This lack of hepatic injury in rat HEV-infected animals 
is in line with earlier reports (Li et al., 2013a; Purcell et al., 2011). 
To study whether the virus is efficiently transmitted infected to sentinel rats, sentinel animals 
were co-housed together with rats that had been infected with strain LA-B350. Following 21 
days of co-housing, all sentinels were found to be infected. High titers of viral RNA were 
detected in the feces of these animals, although these titers were lower than those of the 
originally infected rats (figure 1C). Viral titers further increased until day 28 after the 
beginning of the co-housing. Overall, these data confirm efficient transmission of rat HEV 
between co-housed animals. 
We also attempted to infect several mouse strains with the LA-B350 rat HEV strain. While 
no viral RNA could be detected in the feces or liver of intravenously injected severe 
combined immunodeficient (SCID) and athymic nude mice, low levels of rat HEV RNA were 
detected in 3 out of 3 livers of inoculated AG129 mice (about 106 copies g-1 liver), but not in 
the feces (data not shown). Attempts to passage the virus by injecting other AG129 mice with 
liver homogenates from these 3 infected mice were unsuccessful however. 
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 Human hepatoma cell lines Huh7 and HepG2/C3A support solid LA-B350 replication 
Next, several hepatoma cell lines were inoculated with LA-B350 rat HEV obtained from day 
60 rat livers. In line with earlier findings (Jirintai et al., 2014), solid replication was observed 
in Huh7 and HepG2/C3A cell lines (figure 1E-F). Replication in HepG2/C3A cells was 
somewhat delayed when compared to Huh7 cells. In contrast to the findings of (Jirintai et al., 
2014), we could not detect any replication in PLC/PRF/5 hepatoma cells. The rat hepatoma 
cell line H4IIE did not support rat HEV replication either (data not shown). 
 
Construction and in vitro testing of cDNA clone pLA-B350 
To develop rat HEV LA-B350 as a convenient tool for fundamental and antiviral studies, a 
full-length cDNA clone was constructed of the LA-B350 consensus sequence (pLA-B350, 
figure 2A). Transfection of a capped RNA transcript in Huh7 cells confirmed the in vitro 
replication competence of the pLA-B350 construct with increasing viral titers over 20 days 
(figure 2B). The rather high number of RNA copies at day 3 post transfection probably 
represents RNA remnants of the initial inoculum. Interestingly, the addition of ribavirin to a 
concentration of 50 µM resulted only in a delay in the increase of viral RNA in the culture 
medium, yielding equally high amounts of viral RNA at day 20 post transfection, both in 
culture medium and intracellularly (figure 2B-C). This is in contrast with genotype 3 human 
HEV replication which is strongly inhibited by ribavirin at 50 µM (Debing et al., 2014b). 
 
Intrahepatic inoculation of capped pLA-B350 RNA transcripts results in robust 
infection and shedding of infectious virus 
Next, we assessed the in vivo replication potential of pLA-B350 by injecting capped pLA-
B350 RNA transcripts intrahepatically in 3 athymic nude rats. Viral RNA could be detected 
in the feces 4 days after inoculation and titers increased rapidly over the following 24 days 
(figure 2D), in a similar fashion as observed for rats injected with infectious LA-B350 (figure 
1A). As a negative control, three other rats were injected with non-capped transcripts: robust 
viral shedding was observed in only one of these rats, although with a clear delay compared 
to rats injected with the capped RNA. Quantification of rat HEV RNA in serum and liver 
confirmed these findings (figure 2E-F).This is in line with an earlier report describing the 
necessity of capping for infectivity of genotype 1 HEV RNA in rhesus monkeys (Emerson et 
al., 2001). To assess whether the viral RNA detected in feces and liver indeed represents 
infectious virus, Huh7 cell cultures were inoculated with rat HEV from fecal and liver 
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suspensions from pLA-B350 RNA-inoculated rats at day 28 post injection: release of viral 
RNA in the culture medium was assessed at day 10 and 20 and intracellular levels were 
quantified at day 20 (figure 3). Cultures inoculated with fecal extracts from rats 1-4, but not 
rats 5 and 6, resulted in efficient viral replication (figures 3A-B), whereas viral replication 
was detected in cultures that had been inoculated with liver-extracts of rats 1-5 and 
intracellular rat HEV RNA could be detected for all rats (figure 3C-D), suggesting that a 
limited amount of infectious virus might have been produced in the livers of rats 5 and 6 as 
well. Taken together, these data confirm the infectivity of pLA-B350. 
 
Subgenomic replicon pLA-B350/luc as a tool for antiviral drug testing 
When using rat HEV as an in vivo model for HEV, it would be highly convenient to have a 
tool that allows preliminary in vitro testing of potential antiviral drugs on rat HEV before 
animal testing. To this end, the subgenomic replicon pLA-B350/luc was constructed in which 
a Gaussia luciferase reporter gene was inserted at the ORF2 start codon (figure 4A), similarly 
to the HEV genotype 3 Kernow-C1 p6/luc replicon (Shukla et al., 2012). Capped pLA-
B350/luc RNA was transfected into Huh7 and HepG2/C3A hepatoma cells: solid replication 
was observed in Huh7 cells cultured at 35°C, while luminescence was considerably lower at 
37°C (figure 4B), in line with findings for human HEV strains (Shukla et al., 2012; 
Takahashi et al., 2007). Transfection of HepG2/C3A cells yielded very low luminescence 
values, probably due to transfection toxicity; a phenomenon that we observed earlier for the 
genotype 1 Sar55/S17/luc replicon in these cells (data not shown). Next, pLA-B350/luc was 
employed in a 3-day antiviral assay in Huh7 cells (figure 4C). Interferon alpha potently 
inhibited the replicon with an EC50-value of 10 ± 5 international units (IU) ml
-1, whereas the 
activity of ribavirin was less pronounced (EC50 of 33 ± 9 µM). Interestingly, the activities of 
both compounds are approximately 10-fold weaker as those observed for the genotype 3 
Kernow-C1 p6/luc replicon in the same cell type (Debing et al., 2014b). In line with results 
obtained for ribavirin, the activity of mycophenolic acid, another GTP-depleting drug, was 
limited (EC50 of 3 ± 2 µM, with some toxicity). We also tested sofosbuvir, a potent inhibitor 
of the hepatitis C virus RNA dependent RNA polymerase (RdRp) (Sofia et al., 2010), that 
also exhibits some in vitro antiviral activity against HEV (Dao Thi et al., 2015). Sofosbuvir 
inhibited pLA-B350/luc replication with an EC50 of 12 ± 1 µM, which is very much 
comparable to the inhibition observed in the HEV p6/luc system (Dao Thi et al., 2015). 
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 Partial humanization of the rat HEV RdRp 
To study the role of specific motifs in HEV non-structural proteins and to increase the 
relevance of the rat HEV system, it would be highly useful for the construct/replicon to be 
amenable to humanization, i.e. replacement of certain sequences or motifs by their 
counterparts from human HEV strains. As a proof of concept, we replaced the 
DFVAKLRNV-motif at the RdRp C-terminus of pLA-B350/luc with the corresponding 
DFLRGLTNV sequence from HEV genotype 3, resulting in 4 amino acid changes. This 
specific region was selected given the role of the G1634R mutation in ribavirin treatment 
failure (Debing et al., 2014d). The resulting chimeric pLA-B350/hcRdRp/luc construct 
replicated to a similar extent as the wild-type pLA-B350/luc replicon (figure 4D, p = 0.52, t-
test), illustrating the possibilities for further humanization of the rat HEV system. 
 
Ribavirin inhibits LA-B350 replication in vivo 
Finally, we assessed the suitability of the rat model for in vivo antiviral studies. LA-B350-
infected rats were treated intraperitoneally with either phosphate-buffered saline (PBS) or 
ribavirin at 30 mg kg-1 day-1 for 14 days after infection, followed by 7 days without treatment 
before sacrifice. We detected robust virus shedding in the feces in 6/6 PBS-treated rats, but 
only in 2/6 ribavirin-treated rats (figure 5A). Similarly, viral RNA was detected in all PBS-
treated rat livers, but only in 3/6 livers of the ribavirin group. Overall, significantly more rat 
HEV RNA was found in the livers from the PBS group compared to the ribavirin group: 7.6 x 
108 vs. 4.7 x 107 RNA copies g-1 liver (figure 5B, p = 0.0078, Mann-Whitney U test), 
confirming the efficacy of ribavirin treatment in the rat HEV model, despite a limited in vitro 
antiviral effect.  
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Discussion 
HEV is estimated to cause ~56 600 deaths each year and chronic hepatitis E is increasingly 
recognized as an important problem in the transplant setting (Sayed et al., 2015; WHO, 
2015). Nevertheless, our understanding of the HEV biology is still very limited and 
therapeutic options are few (Debing and Neyts, 2014). This is partially due to the lack of a 
convenient and robust animal model: most in vivo studies to date relied on the use of 
monkeys or pigs (Yugo et al., 2014). Rat HEV represents an interesting opportunity to fill 
this gap: the virus is closely related to human/swine HEV and readily infects laboratory rats 
(Li et al., 2013a; Purcell et al., 2011). Therefore, we developed the necessary tools to use rat 
HEV strain LA-B350 as a bona fide animal model for HEV. LA-B350 readily infects athymic 
nude rats in which it causes a chronic infection, which resembles the situation in 
immunocompromised patients with chronic hepatitis E. A full-length cDNA clone was 
constructed from the LA-B350 consensus sequence and the infectivity of its RNA transcripts 
was shown in vitro and in vivo. Furthermore, we constructed the pLA-B350/luc subgenomic 
replicon that is suitable for in vitro antiviral testing. This allows easy testing of anti-rat HEV 
activity of a molecule before initiating animal studies. Finally, a proof-of-concept was 
provided for the humanization of parts of the rat HEV sequence. 
 
The construction of a cDNA clone of rat HEV strain R63/DEU/2009 was recently reported 
(Li et al., 2015). Contrary to the cDNA clone of this study, which contains 23 mutations 
compared to the original sequence, pLA-B350 is based on the consensus sequence of the LA-
B350 strain and any PCR-induced mutations were corrected. LA-B350 also has the advantage 
of replicating in the commonly used Huh7 and HepG2/C3A hepatoma cell lines, but we could 
not detect solid replication in PLC/PRF/5 cells, contrary to the results for R63/DEU/2009 (Li 
et al., 2015). 
 
An early report on rat HEV indicated a lack of replication in rat liver cell lines such as N1-
S1, clone 9, and MH1C1 (Johne et al., 2010a). In addition, we were unable to culture LA-
B350 in H4IIE rat hepatoma cells. Conversely and surprisingly, human hepatoma cell lines 
such as Huh7, HepG2/C3A and PLC/PRF/5 support solid rat HEV replication (Jirintai et al., 
2014). Although the virus was not transmissible to rhesus monkeys (Purcell et al., 2011), rat 
HEV-specific antibodies have been found in forestry workers (Dremsek et al., 2012). This 
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raises questions about the zoonotic potential of rat HEV. The tools developed in this study 
may contribute to elucidating rat HEV’s role as a zoonotic pathogen. 
 
Another interesting observation is the reduced sensitivity of pLA-B350/luc to the antiviral 
effects of alpha interferon, ribavirin and mycophenolic acid, despite the fact that the same 
Huh7 cell line was employed as in the earlier genotype 3 HEV studies (Debing et al., 2014b). 
We showed earlier that the antiviral effect of both ribavirin and mycophenolic acid depends 
on the depletion of intracellular GTP pools (Debing et al., 2014b), suggesting that the rat 
HEV RdRp may inherently use GTP in a more efficient manner. Despite this reduced 
sensitivity, ribavirin was still able to significantly lower viral loads in vivo, corroborating the 
use of LA-B350 as a HEV surrogate, even if there are differences in sensitivity between rat 
and human HEV. Although we demonstrated that sofosbuvir exerts in vitro activity against 
the rat HEV, the potential protective effect of this compound in the rat infection model cannot 
be studied. Indeed, rats have high levels of esterase activity in the gastrointestinal tract and 
serum which results in rapid degradation of the prodrug moiety of sofosbuvir and as a 
consequence very low amounts of the active 5’-triphosphate in the liver (Dao Thi et al., 
2015). However, the rat model will still be highly useful to study the in vivo antiviral activity 
of other antiviral compounds, both established drugs and novel molecules. 
 
Finally, the successful replacement of part of the rat HEV RdRp with a genotype 3 HEV 
sequence opens possibilities for further humanization of the RdRp and possibly other viral 
proteins, making the model more relevant to the human situation. Such chimeras could also 
be used to study the molecular replication mechanisms of the Hepeviridae or to determine 
viral factors governing host specificity.  
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Materials and methods 
Cells and viruses 
Huh7 cells (a kind gift from Ralf Bartenschlager, University of Heidelberg, Germany) and 
HepG2/C3A cells (a kind gift from Luc Verschaeve, Scientific Institute of Public Health, 
Brussels, Belgium) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Gibco) in a humidified 5% 
CO2 incubator at 37°C. Cell lines were regularly tested for Mycoplasma contamination. 
 
Rat HEV strain LA-B350 (GenBank accession no. KM516906) stock was a 10% liver 
homogenate from rat B350 (kindly provided by Suzanne U. Emerson, National Institute of 
Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD) (Debing et al., 
2014a; Purcell et al., 2011). 
 
Construction of pLA-B350 cDNA clone 
Total RNA was extracted from 100 µl of a 10% liver homogenate from rat B350 with the 
Qiagen RNeasy kit (Hilden, Germany) and rat HEV cDNA was generated using the One-Step 
reverse transcription PCR kit (Qiagen) and KAPA Hi-Fi HotStart ReadyMix PCR kit (Kapa 
Biosystems, Wilmington, MA). Primers were designed based on relatively conserved regions 
in other rat HEV sequences and strain-specific sequences as they became available. 
Fragments were gel-purified, cloned into the pJet1.2 vector using the Clone-JET PCR cloning 
kit (Thermo Fisher Scientific, Waltham, MA), and sequenced as described (Debing et al., 
2014a). Fragments and restriction enzymes used to assemble the full-length cDNA are 
depicted in figure 2A. First, fragments 6 and 7 were fused, followed by the addition of 
fragments 5, 4 and 3. Fragments 1 and 2 were fused together and finally fragments 1-2 and 3-
7 were ligated. Residues not corresponding to the consensus sequence were mutated to match 
the consensus. An XbaI restriction site and T7 promoter sequence were inserted at the 5’ end 
and a 80bp polyA-tail and a MluI restriction site were added at the 3’end. Next, the full-
length T7-LA-B350-polyA was cloned into pBlueScript SK (+) using XbaI and MluI to yield 
pLA-B350. Escherichia coli Top10 cells (Life Technologies, Carlsbad, CA) were 
transformed with ligated plasmid and cultured in 100 ml Terrific Broth (Carl Roth, Kalsruhe, 
Germany) with ampicillin and midiprepped (NucleoBond Xtra midi kit, Macherey-Nagel, 
Düren, Germany).The entire construct was sequenced and mutations not corresponding to the 
consensus sequence were corrected. Primer sequences are available upon request. 
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 Construction of pLA-B350/luc and pLA-B350/hcRdRp/luc replicons 
To construct pLA-B350/luc, the Gaussia luciferase gene was amplified from the Kernow-C1 
p6/luc construct (Shukla et al., 2012), fused to flanking regions of pLA-B350 by fusion PCR 
and inserted into pLA-B350 using AflII and EcoRI. The Gaussia luciferase gene was inserted 
at the ORF2 starting codon (replacing the sequence between positions 4943 and 5285 of 
pLA-B350, figure 4A). 
 
To replace the DFVAKLRNV-motif at the C-terminus of the RdRp (aa 1575-1583 according 
to AIP98381 numbering) with the corresponding human HEV genotype 3 motif 
DFLRGLTNV, PCRs were performed on pLA-B350/luc using primer pairs 5’-
ATGGTGCTTTTATGGCGATTG-3’ + 5’-
CGTCAACCCTCGAAGAAAGTCGCGCACGGAC-3’ and 5’-
CTTCGAGGGTTGACGAATGTCACTGCCTTG-3’ + 5’-
GGCAGCCACTTCTTGAGCAG-3’. Fragments were fused using outer primers and inserted 
into pLA-B350/luc with AflII and NcoI, yielding pLA-B350/hcRdRp/luc. 
 
In vitro transcription and capping 
Viral RNA was in vitro transcribed from MluI-linearized plasmid DNA with the RiboMAX 
Large Scale RNA Production System-T7 (Promega, Madison, WI) and capped with the 
ScriptCap m7G capping system (Cellscript, Madison, WI). Nucleic acid concentrations were 
determined by spectroscopy (Nanodrop ND-1000; Thermo Fischer Scientific). 
 
Antiviral and replicon assays 
Transient replicon experiments and luminescence-based antiviral assays were performed in 
Huh7 cells as previously reported for the HEV Kernow-C1 p6/luc replicon (Debing et al., 
2014b; Debing et al., 2014c; Debing et al., 2014d). Alpha interferon 2b (Intron-A) was 
purchased from Schering-Plough (Kenilworth, NJ). Ribavirin (1-(β-D-ribofuranosyl)-1H-
1,2,4-triazole-3-carboxamide [Virazole]) was purchased from ICN Pharmaceuticals (Costa 
Mesa, CA). Mycophenolic acid was obtained from Santa Cruz Biotechnology (Dallas, TX) 
and sofosbuvir was from Selleckchem (Munich, Germany). 
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 In vitro rat HEV culture 
Huh7 or HepG2/C3A cells were seeded in 6-well plates at 2 x 105 cells per well in 2 ml of 
DMEM with 10% FBS, penicillin (100 units/ml; Gibco) and streptomycin (100 g/ml; Gibco) 
and were incubated at 37°C for 24h. For infection, 10% liver or feces suspensions were 
diluted 1:5 in DMEM with 10% FBS and filtered through a 0.2 µm filter. Culture medium 
was removed and cell layers were inoculated with 1 ml of the resulting solution 
(corresponding to approximately 2 x 108 viral RNA copies). Plates were shaken for 1h at 
room temperature and subsequently incubated at 35°C for 4h. Afterwards, the inoculum was 
removed, cell layers were washed 3 times with 2 ml of PBS, and 2.5 ml of medium was 
added to each well. One ml of the medium was removed every 2-3 days, stored at -80°C and 
1 ml of fresh medium was added to each well. After 20 days, cell layers were lysed and 
intracellular RNA was extracted with the Qiagen RNeasy kit. Viral RNA was extracted from 
culture medium with the NucleoSpin RNA virus kit (Macherey-Nagel, Düren) and quantified 
by reverse-transcription quantitative PCR (RT-qPCR). 
 
To assess the in vitro replication of pLA-B350, Huh7 cells were seeded into 6-well plates at 2 
x 105 cells per well and transfected 24h later with capped RNA transcripts (1 µg per well) 
using Lipofectin (Life Technologies). Ribavirin was either not included in the culture 
medium or added to a concentration of 50 µM. One ml of medium was removed every 2-3 
days, stored at -80°C and 1 ml of fresh medium (with or without ribavirin) was added to each 
well. After 20 days, cell layers were lysed and intracellular RNA was extracted with the 
Qiagen RNeasy kit. To extract viral RNA from culture medium, RNase A (Promega) was 
added to 150 µl of thawed medium to a final concentration of 200 ng/ml and incubated at 
room temperature for 5’ to reduce the amount of residual in vitro transcripts from RNA 
transfection. Viral RNA was extracted with the NucleoSpin RNA virus kit and quantified by 
RT-qPCR. 
 
Animal experiments 
All animal studies were performed in accordance with local institutional guidelines and 
regulations, including approval for all animal experiments by the local Ethical Committee for 
Animal Experiments of KU Leuven, Belgium (project number: P007-2015). Five week-old 
homozygous female athymic nude Hsd:RH-Foxn1rnu rats (Rattus norvegicus; Envigo, Horst, 
the Netherlands) were injected intravenously in the tail vein with 200 µl of a 1% liver 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
homogenate of rat B350 (corresponding to approximately 2 x 107 viral RNA copies, 
generated by homogenizing a liver fragment in PBS to obtain a 10% suspension which was 
subsequently diluted 10-fold before injection) or injected intrahepatically with 5 µg of capped 
or non-capped pLA-B350 RNA (in 40 µl of H2O, spread over 2-3 injection sites). Feces were 
collected every 2-3 days, while serum was collected once a week through the tail-cut method; 
samples were stored at -80°C. For transmission experiments, rats were injected intravenously 
in the tail vein or intrahepatically with 200 µl of rat B350 liver homogenate and infected 
animals were co-housed with non-infected sentinels (n=3 for each group) for three weeks. 
Cage bedding was changed every week. Every morning, sentinels were fasted for two hours. 
For antiviral experiments, ribavirin was dissolved in PBS at 30 mg ml-1 and animals were 
injected intraperitoneally with 1 µl PBS or ribavirin solution per g body weight once daily 
(final dose: 30 mg kg-1 day-1) for 14 days. At the indicated time points, animals were 
sacrificed by intraperitoneal pentobarbital injection and serum and liver tissue were collected. 
For fecal samples, 10% suspensions in PBS were prepared by vortexing. After centrifugation, 
supernatant was used for either infection of cell cultures or for RNA extraction using the 
NucleoSpin RNA virus kit. RNA was extracted directly from serum samples in the same way. 
For liver samples, 10% suspensions were prepared through homogenization in PBS for 
infection of cell cultures or in buffer RLT for subsequent RNA extraction with the Qiagen 
RNeasy kit. 
 
RT-qPCR 
For TaqMan-based quantification of rat HEV RNA, the forward primer 5’-
ATGGTGCTTTTATGGCGATTG-3’ and the reverse primer 5’-
CAAACTCACTGAAATCATTCTCAAAAAC-3’ were used (Purcell et al., 2011). The probe 
was labeled with 6-carboxyfluorescein (FAM) at the 5’ end, ZEN internal quencher in the 
middle and Iowa Black Fluorescent Quencher (IBFQ) at the 3’ end (5’-FAM-TATGTTCAG-
ZEN-GAGAAGTTGGAAGCCGCTGT-IBFQ-3’, Integrated DNA Technologies, Coralville, 
Iowa). Reactions were performed with One-Step qRT-PCR mix (Eurogentec, Seraing, 
Belgium) in a final volume of 25 µl containing 900 nM of each primer, 250 nM of probe, and 
5 µl of RNA sample, using an ABI 7500 Fast real-time PCR system (Applied Biosystems, 
Foster City, CA) under the following conditions: 30 min at 48°C and 10 min at 95°C, 
followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Data were analyzed with ABI Prism 
7500 SDS software (version 1.3.1; Applied Biosystems). For absolute quantification, 
standard curves were generated using 10-fold dilutions of the cloned target cDNA.  
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Serology and histopathology 
Serum ALT, AST and γGT levels were determined with the Roche/Hitachi Cobas c 701/702 
analyzer. For liver histological examination, tissue samples were harvested at indicated time 
points and subsequently fixed in 8% formaldehyde, embedded in paraffin, sectioned and 
stained with hematoxylin-eosin as previously described (Leyssen et al., 2003). The following 
parameters were evaluated for inflammation and liver injury: infiltration of portal tracks by 
lymphocytes and polymorphonuclear leukocytes, ballooned hepatocytes, acidophilic body 
formation and the interlobular necrosis of hepatocytes.  
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Figures 
 
 
 
Fig. 1. Rat HEV strain LA-B350 is infectious in vivo and in vitro. Four athymic nude rats 
were inoculated intravenously with LA-B350 and virus quantities in feces, serum (A), and 
liver (B) were determined by RT-qPCR, documenting robust infection. In a subsequent 
transmission experiment, LA-B350-infected rats were co-housed with non-infected sentinels. 
Sentinels displayed robust shedding of virus in stool after 21 and 28 days, indicating efficient 
transmission of rat HEV (C). Haematoxylin-eosin staining of liver sections showed only very 
limited infiltration of portal tracks with lymphocytes and polymorphonuclear leucocytes in 
infected animals (D). LA-B350 also proved infectious in vitro in Huh7 and HepG2/C3A 
cells: viral RNA released in the culture medium increased over time (E) and high amounts of 
RNA were detected intracellularly after 20 days (F). Values represent mean ± standard error 
of the mean (s.e.m.) for 4 animals (A) or from 3 independent experiments (E-F). The limit of 
detection for panels E-F is approximately 103 RNA copies mL-1 culture medium or µg-1 total 
RNA, respectively. LOD, limit of detection. ** p < 0.01 (two-tailed t-test). 
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Fig. 2. RNA transcripts from cDNA clone pLA-B350 induce robust infection in vitro and 
in vivo. A cDNA clone for LA-B350 was constructed based on the consensus sequence from 
7 overlapping fragments (A). Capped pLA-B350 transcripts were transfected into Huh7 cells 
and induced robust infection (B-C). Intrahepatic injection of capped pLA-B350 RNA in 
athymic nude rats resulted in robust shedding of rat HEV RNA in the feces (D) and serum 
(E), while high amounts of virus were detected in the liver after 28 days (F). Injection of non-
capped RNA only induced successful infection in 1/3 rats. Values represent mean ± s.e.m. 
from 3 independent experiments (A-C) or individual values for each rat (D-F). LOD, limit of 
detection. 
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Fig. 3. Virus progeny from pLA-B350 RNA-injected rats is infectious in cell culture. 
Huh7 cell cultures were inoculated with feces (A-B) or liver (C-D) suspensions from pLA-
B350 RNA-injected rats (28 days post infection). Robust viral replication was observed for 
cultures corresponding to rats 1-3 (capped) and rat 4 (non-capped). Values represent 
individual values for each culture/rat. LOD, limit of detection. 
  
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
dv
an
ce
 a
rt
ic
le
  
Fig.4. Subgenomic replicon pLA-B350/luc is suitable for antiviral testing and is 
amenable to humanization. The pLA-B350/luc subgenomic replicon was constructed by 
inserting a Gaussia luciferase reporter gene downstream of the ORF2 start codon (A). pLA-
B350/luc displayed strong viral replication in Huh7 cells at 35°C, but less at 37°C, whereas 
HepG2/C3A yielded very low luminescence signals, probably due to transfection toxicity 
(B). Dose-response curves represent antiviral effects and cell viability for alpha interferon, 
ribavirin, mycophenolic acid and sofosbuvir (C). Part of the C-terminal RdRp sequence of 
pLA-B350/luc was replaced with its genotype 3 HEV counterpart, without affecting viral 
replication (D). Values represent mean ± s.e.m. from 3 independent experiments. 
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Fig.5. Ribavirin treatment of LA-B350-infected rats delays virus shedding and 
significantly reduces viral loads in the liver. Twelve rats were infected intravenously with 
rat HEV LA-B350. Afterwards, 6 of these rats were injected daily with ribavirin at 30 mg/kg 
(red), whereas the other 6 were injected with PBS (black), for 14 days. Rat HEV was 
quantified in feces (A) and in liver 21 days after infection (B). Values represent individual 
values for each rat, significance was calculated through the Mann-Whitney U test (B). LOD, 
limit of detection. 
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